Plaquenil

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

cGMP Non-Compliance Recap 2020

The coronavirus pandemic changed the way we lived our lives, and regulatory agencies were no except

New Drugs Approvals by FDA and EMA: 2020 Recap

The year 2020 was an eventful year for the pharmaceutical industry, with several companies across

Covid-19 HCQ update: Studies in France, Brazil, China raise more questions on its efficacy, safety

Last month, we had carried an article ‘Hydroxychloroquine: Hype versus reality’ that hi

Chinese industrial activity revival at 98.6 percent, officials assure of API supplies

While the world feels the heat of the Covid-19 pandemic with the global pharmaceutical supply chain

Hydroxychloroquine: Hype versus reality

The President of United States Donald Trump’s tweet late last week has swung the pharmaceut

Teva to market cannabis inhaler; FDA makes quality metrics voluntary

This week, Phispers brings you news on J&J’s plans to acquire Actelion and Teva’s ne

The silver lining in Ipca’s Import Alert blues

Ipca Laboratories finished dosage facilities at Silvasa and Pithampur (India) were put on the FDA Im

With a $1.2 billion buy, Concordia re-affirms that old drugs are indeed gold!

Canada based, Concordia Healthcare continued their buying spree of old, established drug brands